<DOC>
	<DOCNO>NCT00866515</DOCNO>
	<brief_summary>This single-centre , randomise , double blind , placebo control , two-way crossover study healthy male female subject . There two treatment period consist 7 day . During treatment period subject receive single dos ketoconazole placebo morning day 1-6 single dose GW642444M morning Day 5 .</brief_summary>
	<brief_title>Drug Interaction Study Investigate Co-administration GW642444M With Ketoconazole</brief_title>
	<detailed_description>This single-centre , randomise , double blind , placebo control , two-way crossover study healthy male female subject . There two treatment period consist 7 day . During treatment period subject receive single dos ketoconazole placebo morning day 1-6 single dose GW642444M morning Day 5 .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include discretion Investigator find unlikely introduce additional risk factor interfere study procedure . AST , ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation , hysterectomy bilateral oophorectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . Childbearing potential agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception final followup visit complete . Body weight ≥ 50 kg BMI within range 19 29.9 kg/m2 ( inclusive ) . Demonstrated ability use inhaler device satisfactory repeatable manner Subjects current nonsmoker , use inhale tobacco product ( snuff permit ) 12 month period precede screen visit pack history ≤ 10 pack year . No significant abnormality 12lead ECG screening , include follow requirement : Ventricular rate ≥ 40 beat per minute PR interval ≥ 120 ≤ 210 msec Q wave &lt; 30 msec ( 50 msec permit lead III ) QRS interval ≥ 60 msec ≤ 120 msec QTc interval must &lt; 450 msec ( QTcB QTcF ; machine manual reading ) base average three ECGs obtain brief recording period FEV1 ≥ 80 % predict FEV1 / FVC ratio ≥ 0.7 screen Capable give write informed consent , include compliance requirement restriction list consent form . As result medical interview , physical examination screen investigation , principle investigator delegate physician deems subject unsuitable study . Systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg heart rate outside range 40 90 bpm . The subject treat diagnosed depression within six month screen history significant psychiatric illness . The subject history breathing problem adult life ( i.e . history asthmatic symptomatology ) . A clinically significant abnormality standard pulmonary function testing , find would prevent satisfactory administration inhale study medication . Any contraindication administration ketoconazole , describe current [ NIZORAL Product Information , JanssenCilag Pty Limited , 2008 ] . History sensitivity study medication , component thereof ( include milk protein ) history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Currently take regular ( course ) medication whether prescribed , exception permit medication list Section 8.1 Section 9.1 . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~250 mL ) beer , 1 glass ( 100 mL ) wine 1 measure ( 30 mL ) spirit . The subject participate clinical trial receive drug new chemical entity within 30 day 5 halflives , twice duration biological effect drug ( whichever longer ) prior first dose current study medication . Exposure four new chemical entity within 12 month prior first dose day . The subject donate unit blood within previous 16 week intend donate within 16 week complete study . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . The subject test positive HIV antibody . The subject positive prestudy urine drug screen/ alcohol breath test . A minimum list drug screen include Amphetamines , Barbiturates , Cocaine , Opiates , Cannabinoids Benzodiazepines . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . Subjects screen haemoglobin value &lt; 110 mg/L . Pregnant ( determine positive ( serum urine ) hCG test screen prior dose ) lactate female . Subject mentally legally incapacitate . CO breath monitor indicative smoking history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Ketoconazole</keyword>
	<keyword>Drug Interaction</keyword>
	<keyword>pharmacokinetcs</keyword>
	<keyword>GW642444M</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>